Quadrant Biosciences

Quadrant Biosciences, led by company founder and CEO Richard Uhlig, has a well-balanced management team dedicated to promoting the continuous development, testing, and distribution of its products. The team includes expertise in engineering, FDA regulatory compliance, manufacturing, marketing, and sales. Two evolutionary advancements in concussion assessment and autism detection will significantly impact how clinicians diagnose and treat these serious conditions. Quadrant Biosciences collaborates with top academic institutions, medical researchers, and engineers to transform groundbreaking discoveries into carefully considered and scientifically sound epigenetic diagnostic tools. These breakthrough tools are part of the evolving Clarifi diagnostic platform, addressing various neurological health challenges. The Clarifi Autism Saliva Test (Clarifi ASD) is the first molecular test of its kind for autism. Clarifi ASD is designed to assist in the clinical diagnosis of ASD in children aged 18 months to 6 years, accelerating access to crucial intervention services. When treatment is most effective, Clarifi ASD provides biological support for early diagnosis. Clarifi ASD was co-developed with the State University of New York Upstate Medical University and the Penn State College of Medicine.